European Journal of Internal Medicine
Volume 21, Issue 4 , Pages 293-296 , August 2010

The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients

  • L.E. Degreef

      Affiliations

    • Section of Vascular Medicine, Department of Endocrinology & General Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands
    • ,
  • F.L. Opdam

      Affiliations

    • Section of Vascular Medicine, Department of Endocrinology & General Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands
    • ,
  • I.M. Teepe-Twiss

      Affiliations

    • Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands
    • ,
  • J.W. Jukema

      Affiliations

    • Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands
    • ,
  • H.J. Guchelaar

      Affiliations

    • Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands
    • ,
  • J.T. Tamsma

      Affiliations

    • Section of Vascular Medicine, Department of Endocrinology & General Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands
    • Corresponding Author InformationCorresponding author. Section of Vascular Medicine, Department of Endocrinology & General Internal Medicine, Leiden University Medical Center, Albinusdreef 2, PO box 9600, 2300 RC Leiden, The Netherlands. Tel.: +31 715262998; fax: +31 715248140.

Received 8 January 2010 ,Revised 25 March 2010 ,Accepted 28 March 2010.

References 

  1. Corsini A, Windler E, Farnier M. Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol. Eur J Cardiovasc Prev Rehabil. 2009;16(1):1–9
  2. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomized controlled trials. BMJ. 2009;338:b2376
  3. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14(Suppl 2):S1–S113
  4. Ward S, Lloyd JM, Pandor A, Holmes M, Ara R, Ryan A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11(14):1–160iii-iv
  5. Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther. 2007;29(2):253–260
  6. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009;150(12):858–868
  7. Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002 Aug 7;40(3):567–572
  8. Arora R, Liebo M, Maldonado F. Statin-induced myopathy: the two faces of Janus. J Cardiovasc Pharmacol Ther. 2006 Jun;11(2):105–112
  9. Baer AN, Wortmann RL. Myotoxicity associated with lipid-lowering drugs. Curr Opin Rheumatol. 2007;19(1):67–73
  10. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol. 2007;18(4):401–408
  11. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De BG, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003
  12. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278
  13. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423
  14. Matalka MS, Ravnan MC, Deedwania PC. Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS). Am Heart J. 2002;144(4):674–677
  15. Ferrer-Garcia JC, Perez-Silvestre J, Martinez-Mir I, Herrera-Ballester A. Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia. Acta Diabetol. 2006;43(3):75–78
  16. Gadarla M, Kearns AK, Thompson PD. Efficacy of rosuvastatin (5mg and 10mg) twice a week in patients intolerant to daily statins. Am J Cardiol. 2008;101(12):1747–1748
  17. Ruisinger JF, Backes JM, Gibson CA, Moriarty PM. Once-a-week rosuvastatin (2.5 to 20mg) in patients with a previous statin intolerance. Am J Cardiol. 2009;103(3):393–394
  18. Backes JM, Moriarty PM, Ruisinger JF, Gibson CA. Effects of once weekly rosuvastatin among patients with a prior statin intolerance. Am J Cardiol. 2007;100(3):554–555
  19. Mackie BD, Satija S, Nell C, Miller J, Sperling LS. Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy. Am J Cardiol. 2007;99(2):291
  20. Mol MJ, Erkelens DW, Leuven JA, Schouten JA, Stalenhoef AF. Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia. Lancet. 1986;2(8513):936–939
  21. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1 variants and statin-induced myopathy — a genowide study. N Engl J Med. 2008;359(8):789–799

☆ This manuscript is written without any conflict of interest.

PII: S0953-6205(10)00058-0

doi: 10.1016/j.ejim.2010.03.015

European Journal of Internal Medicine
Volume 21, Issue 4 , Pages 293-296 , August 2010

Article Tools

* Image Usage & Resolution